Fundraising Fox

BioAdvance

Venture capital

Conshohocken · Pre-Seed–Late Stage · 6 people tracked

Fox Verdict
Sign up to see your fit
Stage
Pre-Seed–Late Stage
Check
$250K – $1.5M
HQ
Conshohocken, Pennsylvania, US
Instruments
Debt · Equity
Founded
2002
AUM
$80M

Team · 6 people

from the firm's website

Frequently asked questions

What stage does BioAdvance invest at?
BioAdvance invests at the Pre-Seed, Seed, Series A, Late Stage stages.
What is BioAdvance's typical check size?
BioAdvance typically writes checks of $250K – $1.5M.
What sectors does BioAdvance focus on?
BioAdvance focuses on Biotech, Medical Devices.
Where is BioAdvance located?
BioAdvance is headquartered in Conshohocken, US.

Similar investors

B Capital Group

B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.

DCVC (Data Collective)

DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.

Khosla Ventures

Khosla Ventures is a technology-focused investment firm that seeks companies leveraging disruptive technological advances to solve large-scale problems across multiple industries. The firm emphasizes proprietary technology, business model innovation, and early-stage, bold investments with unfair advantages.

$5K – $50M
Medicxi

A European investment firm established in 2016 by former Index Ventures life sciences professionals with over 20 years of experience in drug discovery and therapeutic development for unmet medical needs.

Osage University Partners

Osage University Partners is a venture capital firm founded in 2009 that invests in breakthrough startups emerging from leading research labs and university innovation ecosystems. The firm focuses on technology (software, hardware, climate tech) and life science (therapeutics, medtech, diagnostics, research tools) companies across all stages from pre-seed through crossover, leveraging partnerships with over 150 universities and research institutions globally.

$1M – $20M

Featured in lists